Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. Ľupták, M., Michaličková, D., Fišar, Z., Kitzlerová, E., & Hroudová, J. World Journal of Psychiatry, 11(7):277–296, July, 2021. ![Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Schizophrenia is a severe psychiatric disorder characterized by emotional, behavioral and cognitive disturbances, and the treatment of schizophrenia is often complicated by noncompliance and pharmacoresistance. The search for the pathophysiological mechanisms underlying schizophrenia has resulted in the proposal of several hypotheses to explain the impacts of environmental, genetic, neurodevelopmental, immune and inflammatory factors on disease onset and progression. This review discusses the newest insights into the pathophysiology of and risk factors for schizophrenia and notes novel approaches in antipsychotic treatment and potential diagnostic and theranostic biomarkers. The current hypotheses focusing on neuromediators (dopamine, glutamate, and serotonin), neuroinflammation, the cannabinoid hypothesis, the gut-brain axis model, and oxidative stress are summarized. Key genetic features, including small nucleotide polymorphisms, copy number variations, microdeletions, mutations and epigenetic changes, are highlighted. Current pharmacotherapy of schizophrenia relies mostly on dopaminergic and serotonergic antagonists/partial agonists, but new findings in the pathophysiology of schizophrenia have allowed the expansion of novel approaches in pharmacotherapy and the establishment of more reliable biomarkers. Substances with promising results in preclinical and clinical studies include lumateperone, pimavanserin, xanomeline, roluperidone, agonists of trace amine-associated receptor 1, inhibitors of glycine transporters, AMPA allosteric modulators, mGLUR2-3 agonists, D-amino acid oxidase inhibitors and cannabidiol. The use of anti-inflammatory agents as an add-on therapy is mentioned.
@article{luptak_novel_2021,
title = {Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets},
volume = {11},
issn = {2220-3206},
url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311514/},
doi = {10.5498/wjp.v11.i7.277},
abstract = {Schizophrenia is a severe psychiatric disorder characterized by emotional, behavioral and cognitive disturbances, and the treatment of schizophrenia is often complicated by noncompliance and pharmacoresistance. The search for the pathophysiological mechanisms underlying schizophrenia has resulted in the proposal of several hypotheses to explain the impacts of environmental, genetic, neurodevelopmental, immune and inflammatory factors on disease onset and progression. This review discusses the newest insights into the pathophysiology of and risk factors for schizophrenia and notes novel approaches in antipsychotic treatment and potential diagnostic and theranostic biomarkers. The current hypotheses focusing on neuromediators (dopamine, glutamate, and serotonin), neuroinflammation, the cannabinoid hypothesis, the gut-brain axis model, and oxidative stress are summarized. Key genetic features, including small nucleotide polymorphisms, copy number variations, microdeletions, mutations and epigenetic changes, are highlighted. Current pharmacotherapy of schizophrenia relies mostly on dopaminergic and serotonergic antagonists/partial agonists, but new findings in the pathophysiology of schizophrenia have allowed the expansion of novel approaches in pharmacotherapy and the establishment of more reliable biomarkers. Substances with promising results in preclinical and clinical studies include lumateperone, pimavanserin, xanomeline, roluperidone, agonists of trace amine-associated receptor 1, inhibitors of glycine transporters, AMPA allosteric modulators, mGLUR2-3 agonists, D-amino acid oxidase inhibitors and cannabidiol. The use of anti-inflammatory agents as an add-on therapy is mentioned.},
number = {7},
urldate = {2021-11-28},
journal = {World Journal of Psychiatry},
author = {Ľupták, Matej and Michaličková, Danica and Fišar, Zdeněk and Kitzlerová, Eva and Hroudová, Jana},
month = jul,
year = {2021},
pmid = {34327122},
pmcid = {PMC8311514},
pages = {277--296},
}
Downloads: 0
{"_id":"tvZWS3F7qxLXej3P5","bibbaseid":"uptk-michalikov-fiar-kitzlerov-hroudov-novelapproachesinschizophreniafromriskfactorsandhypothesestonoveldrugtargets-2021","author_short":["Ľupták, M.","Michaličková, D.","Fišar, Z.","Kitzlerová, E.","Hroudová, J."],"bibdata":{"bibtype":"article","type":"article","title":"Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets","volume":"11","issn":"2220-3206","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311514/","doi":"10.5498/wjp.v11.i7.277","abstract":"Schizophrenia is a severe psychiatric disorder characterized by emotional, behavioral and cognitive disturbances, and the treatment of schizophrenia is often complicated by noncompliance and pharmacoresistance. The search for the pathophysiological mechanisms underlying schizophrenia has resulted in the proposal of several hypotheses to explain the impacts of environmental, genetic, neurodevelopmental, immune and inflammatory factors on disease onset and progression. This review discusses the newest insights into the pathophysiology of and risk factors for schizophrenia and notes novel approaches in antipsychotic treatment and potential diagnostic and theranostic biomarkers. The current hypotheses focusing on neuromediators (dopamine, glutamate, and serotonin), neuroinflammation, the cannabinoid hypothesis, the gut-brain axis model, and oxidative stress are summarized. Key genetic features, including small nucleotide polymorphisms, copy number variations, microdeletions, mutations and epigenetic changes, are highlighted. Current pharmacotherapy of schizophrenia relies mostly on dopaminergic and serotonergic antagonists/partial agonists, but new findings in the pathophysiology of schizophrenia have allowed the expansion of novel approaches in pharmacotherapy and the establishment of more reliable biomarkers. Substances with promising results in preclinical and clinical studies include lumateperone, pimavanserin, xanomeline, roluperidone, agonists of trace amine-associated receptor 1, inhibitors of glycine transporters, AMPA allosteric modulators, mGLUR2-3 agonists, D-amino acid oxidase inhibitors and cannabidiol. The use of anti-inflammatory agents as an add-on therapy is mentioned.","number":"7","urldate":"2021-11-28","journal":"World Journal of Psychiatry","author":[{"propositions":[],"lastnames":["Ľupták"],"firstnames":["Matej"],"suffixes":[]},{"propositions":[],"lastnames":["Michaličková"],"firstnames":["Danica"],"suffixes":[]},{"propositions":[],"lastnames":["Fišar"],"firstnames":["Zdeněk"],"suffixes":[]},{"propositions":[],"lastnames":["Kitzlerová"],"firstnames":["Eva"],"suffixes":[]},{"propositions":[],"lastnames":["Hroudová"],"firstnames":["Jana"],"suffixes":[]}],"month":"July","year":"2021","pmid":"34327122","pmcid":"PMC8311514","pages":"277–296","bibtex":"@article{luptak_novel_2021,\n\ttitle = {Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets},\n\tvolume = {11},\n\tissn = {2220-3206},\n\turl = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311514/},\n\tdoi = {10.5498/wjp.v11.i7.277},\n\tabstract = {Schizophrenia is a severe psychiatric disorder characterized by emotional, behavioral and cognitive disturbances, and the treatment of schizophrenia is often complicated by noncompliance and pharmacoresistance. The search for the pathophysiological mechanisms underlying schizophrenia has resulted in the proposal of several hypotheses to explain the impacts of environmental, genetic, neurodevelopmental, immune and inflammatory factors on disease onset and progression. This review discusses the newest insights into the pathophysiology of and risk factors for schizophrenia and notes novel approaches in antipsychotic treatment and potential diagnostic and theranostic biomarkers. The current hypotheses focusing on neuromediators (dopamine, glutamate, and serotonin), neuroinflammation, the cannabinoid hypothesis, the gut-brain axis model, and oxidative stress are summarized. Key genetic features, including small nucleotide polymorphisms, copy number variations, microdeletions, mutations and epigenetic changes, are highlighted. Current pharmacotherapy of schizophrenia relies mostly on dopaminergic and serotonergic antagonists/partial agonists, but new findings in the pathophysiology of schizophrenia have allowed the expansion of novel approaches in pharmacotherapy and the establishment of more reliable biomarkers. Substances with promising results in preclinical and clinical studies include lumateperone, pimavanserin, xanomeline, roluperidone, agonists of trace amine-associated receptor 1, inhibitors of glycine transporters, AMPA allosteric modulators, mGLUR2-3 agonists, D-amino acid oxidase inhibitors and cannabidiol. The use of anti-inflammatory agents as an add-on therapy is mentioned.},\n\tnumber = {7},\n\turldate = {2021-11-28},\n\tjournal = {World Journal of Psychiatry},\n\tauthor = {Ľupták, Matej and Michaličková, Danica and Fišar, Zdeněk and Kitzlerová, Eva and Hroudová, Jana},\n\tmonth = jul,\n\tyear = {2021},\n\tpmid = {34327122},\n\tpmcid = {PMC8311514},\n\tpages = {277--296},\n}\n\n","author_short":["Ľupták, M.","Michaličková, D.","Fišar, Z.","Kitzlerová, E.","Hroudová, J."],"key":"luptak_novel_2021","id":"luptak_novel_2021","bibbaseid":"uptk-michalikov-fiar-kitzlerov-hroudov-novelapproachesinschizophreniafromriskfactorsandhypothesestonoveldrugtargets-2021","role":"author","urls":{"Paper":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311514/"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/saracatanese","dataSources":["eTsH756eicg6vxuG3","5Q3QAaq7NKyE2QC5S"],"keywords":[],"search_terms":["novel","approaches","schizophrenia","risk","factors","hypotheses","novel","drug","targets","ľupták","michaličková","fišar","kitzlerová","hroudová"],"title":"Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets","year":2021}